Moxifloxacin (MFX) is a potential oral agent use in the treatment of multidrug-resistance tuberculosis (MDR-TB). Due to variability in pharmacokinetics and in vitro susceptibility of causative bacteria, therapeutic drug monitoring (TDM) of MFX is recommended. Conventional plasma sampling for TDM is facing logistical challenges, especial in limited resource areas, and dried blood spots (DBS) sampling may offer a chance to overcome this problem. The objective of this study was to develop a LC-MS/MS method for determination of MFX in dried blood spots (DBS) that is applicable for TDM.
INtrODUctION
Fluoroquinolones play a crucial role in MDR-TB treatment regiment [1] . Moxifloxacine (MFX) is one of the most promising drug of this group with high in vitro and in vivo activity and is well tolerated [2] [3] [4] . Furthermore, MFX may be useful in extensively drug-resistant tuberculosis (XDR-TB) [5] . MFX appeared to be effective in shortening tuberculosis treatment if it is added to or substituted for an agent in the standard regimen [6] . In selected patient populations (e.g. HIV and tuberculosis meningitis), MFX is a potential candidate to become part of the routine treatment [7, 8] .
Although MFX is frequently used in the treatment of tuberculosis, the optimal dosage of MFX in tuberculosis treatment is not clearly defined [9] . The in vitro pharmacodynamic infection model showed optimized efficacy using a dosage of 800 mg per day, while 400 mg per day is given in daily practice [1, 7, 9] . Furthermore, a significant drop in area under the curve (AUC) of MFX of approximately 30% is observed if rifampicin as an enzyme inducer is administered concomitantly [10] . Taking these facts in consideration, a TDM may help to avoid too low blood levels and to improve the treatment outcomes [11] . Unfortunately, facilities for determination drug level in remote rural areas are not available. As blood samples are unstable at room temperature and cooled shipment is not feasible, the application of DBS sampling is a potential solution to overcome these logistical problems. Although MFX is stable in plasma at the room temperature for at least 5 days [12] long distance transport may take more time or room temperature may be exceeded during transport. DBS sampling has also other advantages including easily to perform; lower risk of infection and the required blood sample volume is smaller [13, 14] . Although the influence of HT and volume of the bloodspot (V b ) were emphasized as potential confounding factors, these may vary for each drug. Therefore HT and V b need to be investigated in DBS method development [13] [14] [15] [16] [17] [18] [19] .
Up to now, DBS method had been developed for the pharmacokinetics and TDM of a number of drugs [13, 14, 20] . As DBS proved its value in TDM of HIV drugs it may also help to optimize the treatment of tuberculosis (TB), especially with MDR-TB.
Clinical validation is highly recommended for DBS method development because HT, viscosity, and consistence of blood may vary between patients. In the clinical validation the relation between the plasma concentration and the concentration of the drug in whole blood (plasma-blood cell partition coefficient) can be determined. The result obtained with DBS can be translated to the reference value which have been determined in serum or plasma value using the blood/plasma ratio [13] .
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The objectives of our study are to develop a LC-MS/MS method for determination of MFX in DBS, and to investigate the effect of influencing factors of this method of sampling and matrix on DBS method development. 
MAtErIALs AND MEtHODs chemicals and reagents

Sample preparation
Stock solutions of MFX were prepared as stock A and stock B by dissolving MFX HCl in water at concentration of 200 mg/L in order to make calibration standards and quality control (QC) samples. The stock solutions were diluted to working stock solutions of 10 mg/L (working stock A1 and B1).
Packed red blood cells (RBC) were centrifuged and the preserving solution was discarded.
The subsequent cells were washed three times with physiological buffer and one time with serum before adding a precise volume of serum to produce pooled blood with the HT of 20, 35 and 50%.
Calibration blood was prepared at concentrations of 0.05, 0.15, 0.50, 1.00, 2.00, 3.50, 5.00 and 6.00 mg/L by adding stock solution A or A1. QC samples, including LLOQ (lower limit of quantitation), LOW, MED, HIGH, OC (over the calibration curve) at concentration of 0.05, 3.2 0.15, 2.50, 5.00 and 10.00 mg/L, respectively, were prepared from stock solution B and B1 by the same method. All tests for the validation were performed using the HT of 35% except for the evaluation of the HT effect itself.
To prepare a DBS, 50 μL of blood was transferred onto paper by an Eppendorf pipette. It was left to dry for at least 3 hours at room temperature and then preserved in a sealed plastic bags at -80°C. Each QC level was prepared in six folds of which five were analyzed.
The extracting solution consisted of cyanoimipramine 0.03 mg/L in a mixture of methanol and water (9:1, v/v). An 8 mm diameter disc was punched out from the DBS and was then transferred to a 1.5 mL Eppendorf tube where 300 μL of extracting solution was added. The extraction was accelerated by 60 minutes of sonication. After sonication 200 μL of the extract was transferred to a polypropylene vial and 5 μL was injected into the LC-MS/MS system. The Thermo TSQ Quantum Discovery mass selective detector was used in positive ion mode and performed selected reaction monitoring as scanning mode. The mass parameters of 
Equipment and conditions
MEtHOD DEvELOpMENt AND vALIDAtION
Method development
To determine MFX in a DBS, a fixed diameter disc is punched out from DBS. Normally, it is assumed that blood volumes in different discs are equal. However, paper type, blood viscosity, that mostly relates to HT, and V b , were possible factors introducing analytical bias [13, 14, 19] . As a consequence, we evaluated the variation in disc-weight and blood spreading with three types of paper including Whatman grade 3, Whatman 31ET CHR and Whatman 903.
From each of six paper cards taken randomly, six blank paper discs were punched out and scaled to determine disc-weight variation. In addition, a precise blood volume of 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 and 60 μL with a HT of 20, 35 and 50% was pipetted on the paper in 6 fold. From both sides of the blood spots, images were taken using a Nikon D60 camera.
Areas of blood spots were measured by image analysis using ImageJ® software (version 1.42q). The V est was calculated using the equation:
In Eq. (1), d is diameter of the punch (8 mm solution, the sonication time of 0, 10, 30, 60 and 100 min was evaluated and the optimal value was selected. The DBS at concentration of 2.5 mg/L was used in the method development.
Method validation
The method was validated in terms of linearity, selectivity and specificity, accuracy, precision, dilution integrity, carry-over, process efficiency and stability [21] . Validation was performed with a maximum tolerated bias and coefficient of variation (CV) of 20% for the LLOQ and 15% for the other validation concentrations. In addition, the influence of HT and V b were also evaluated.
On each of three consecutive days, a single calibration curve with eight concentration levels was analyzed. Calibration curves were then established using 1/x weighted linear regression.
Peak height ratios of MFX and the internal standard were used to calculate concentrations.
Inter and intra-day reproducibility was evaluated at LLOQ, LOW, MED, HIGH and OC levels.
The extract at OC level was diluted ten times with the extract of a blank DBS and the analytical result was then multiplied by ten to correct for the dilution. Selectivity and specificity were In addition, the matrix effect was also investigated by injecting the extracts of five DBS samples derived from finger pricks of MFX free volunteers while MFX and cyanoimipramine neat solution were post-column infused [22] .
The stability of processed samples after 24 and 48 hours stored in the auto-sampler was evaluated by re-injecting the extracts of previous days and calibrated by a freshly prepared calibration curve. Long-term stability was investigated for -80°C, room condition (25°C and 50% of humidity), high temperature (50°C) and high humidity (~100% at room temperature) at 2 weeks and 4 weeks after DBS preparation. High humidity environment was created by storing DBS in a sealed plastic bag with wet tissues without contacting with DBS paper and monitored by a hygrometer.
Influence of HT and V b
Tuberculosis patients have a relatively low HT value of approximately 35 ± 6% [23] . 
C corrected is the concentration after correcting for HT; C observed is the concentration before correcting for HT; V std is the V est at standardized HT (35%); HT is the HT of corrected sample;
b is the regression coefficient between V est (µL) and HT (%)
Blood volumes of 30, 50 and 100 μL were used to make different DBS sizes. Discs were punched out from the central part of the DBS and analyzed in five fold. Calibration samples with a blood volume of 50 μL were used to calculate the influence of V b .
Clinical validation
The samples for clinical validation were taken from tuberculosis patients who received MFX 400 mg once daily orally as part of their treatment .The study protocol was approved by the local institutional ethics committee. Written informed consent was obtained from the patients. Venous blood sampling with a volume of about 3 ml was performed by nurses before the intake of the drug and at 1, 2, 3, 4 and 8 h after oral administration. At each sampling time, a venous DBS was prepared by pipetting 50 µL of the venous blood onto the paper. The remaining venous blood was centrifuged at 3,000 rpm and the plasma was withdrawn and stored at -20°C until analysis. In addition, at the time of pre-dosing, 2 and 8 h post-dose, finger pricks were taken and blood was dropped directly on the paper to make the finger prick DBS. The DBS were left dried for at least 3 h and then stored in a sealed plastic bag at -80°C before analysis. The DBS samples were analyzed using the developed Dried blood spot: Moxifloxacin 59 3.2 method and the plasma samples were analyzed by the routine analytical method in our laboratory [12] . The correlations between venous DBS, DBS from finger prick and plasma concentrations were evaluated by simple linear regression and Passing&Bablok regression with the help of Analyse-it® software.
rEsULts
Method development
The evaluation of the different types of filter paper showed that disc weight relates to the paper's thickness and its matrix. The variation in disc weight may contribute to the variation of V est and subsequently to the analytical result. Among the three types of paper tested the Whatman 31ET CHR showed the smallest variation in disc weight with a CV of 2.3% (table 2).
With the assumption that blood equally spreads from the centre to peripheral of the DBS, V est apparently represents blood volume in a punched disc. Linear regression analysis showed that HT and V b highly contributed to the variation of V est but was not equal among different types of paper. Whatman 31ET CHR showed the highest R 2 of 0.89 which means 89% of variation in V est can be explained by the regression model for this type of paper. Furthermore, the effect of the V b was of no significant influence (β Vb =0.03, p=0.246) suggesting that blood equally spreads on this paper regardless the size of DBS. In contrast, HT is an important predictor which explains 88% (equal to β 2 HT ) of total variation of the V est . If the results are corrected for HT, the accuracy of the DBS method can be improved. For the other two types of paper the lower R 2 value suggested that the variation in V est is less explained by the HT and V b . In addition, the contributions of these parameters are not unique because β HT and β Vb vary among different paper types (table 2) . CHR showed a high correlation between the bias of V est and HT. Based upon these results the Whatman 31ET CHR was selected for the method development.
The extract in water was dark and not suitable for injecting into the LC-MS/MS system. We did not intend to develop another step to clean this extract because it required a more complicated procedure. In addition, MFX appeared to be poorly extracted by ACN or the mixture of ACN:MeOH (16:84 v/v %) because a very low response was observed. The extract in MeOH was clear and produced a high chromatographic response. By adding 10 or 20% of water, the chromatographic response was improved. However, with 20% water, the extract became darker and therefore the mixture of 10% MeOH was selected. During the optimization of the extraction peak height responses increased with increasing sonication time. The maximum extraction performance was achieved at 60 minutes, where no significant difference was observed between 60 and 100 min (p=0.43) (figure 1). Therefore, 60 min of sonication was selected to be used in the method validation.
Method validation
Selectivity and interference
No interfering peaks at the retention time of MFX and cyanoimipramine were observed in the chromatograms of 5 blank blood DBS samples. The responses of blank DBS samples were lower than 4% of those of the LLOQ DBS. These results showed that the method is selective and specific (figure 2). The results of inter and intra-day reproducibility, with respect to bias and precision were within accepted range for all QC levels, with a maximum bias of -8.1% and a maximum CV of 8.7%. The maximum bias and CV of the OC samples after correcting for the dilution were -11.1% and 5.8%, respectively (table 3) .
Linearity, accuracy and precision
Dried blood spot: Moxifloxacin 61 3.2
Figure 1 Influence of sonication time on the response of DBS extracts (n=5).
Results were presented as mean ± SD. 
Stability
The stability of processed samples in the auto-sampler was evaluated at 24 and 48 hours and complied with the validation criteria. For long-term stability, the DBS samples were stable at room conditions for 2 and 4 weeks. However, high humidity and high temperature significantly accelerated the degradation of MFX in DBS as the MFX amounts decreased up to -33.5% bias (table 5) . This indicates that the samples should not be exposed to high temperatures and extremely high humidity.
Influence of HT and V b
The regression equation between V est and HT was: 
Clinical validation
For clinical validation, the plasma, venous DBS and DBS from finger prick samples were taken from 6 tuberculosis patients with hematocrit values of 26, 37, 33, 41, 35 and 38%. The 
DIscUssION
We developed a method of analysis for routine monitoring of MFX using dried blood spot sampling. Our method was based on punching and extracting a part of the collected blood spot using LC/MS/MS. Validation was performed according to the guidelines for bioanalytical method validation. Effect of HT and V b were evaluated as part of this validation. The method is 
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suitable for clinical pharmacokinetic studies and routine monitoring of MFX in daily practice.
To the best of our knowledge this is the first described validation using DBS for MFX.
The HT value and blood volume showed to have a relation with the size of blood spot. Blood with a high HT shows an increased viscosity resulting in a smaller bloodspot. This factor needs to be addressed if the blood is not obtained with a volumetric capillary and only part of the spot is extracted and analyzed. However, sampling with a finger prick without volumetric capillary is easier and cheaper and can therefore be preferred in case of sampling in remote rural areas. In a clinical setting, it is difficult to control the size of the DBS without using a volumetric device. The effect of the size of the DBS on the bias of the result appeared to have less impact than the effect of the HT. The concentration of the DBS showed to be directly proportional to the blood volume it was created with. Although the volume of the bloodspot showed to be of influence, the differences were well within 15% bias ( figure 5 ). Because the discs were punched out from the central part of the DBS, the possible reason could be the chromatographic effect of the paper in which MFX distributed more in the central and less at the peripheral part. This experiment proved that it is best to create bloodspots that show low variation in volume. On the other hand variation in volumes of 30-100 µL between patient blood spots will still be within validation requirements.
An ion enhancement caused by ethylenediaminetetraacetic acid (EDTA) on MFX analysis was reported earlier [12] . We also experienced ion enhancement with DBS prepared from fresh frozen plasma that contained citrate as anticoagulant. For that reason, we selected serum to prepare DBS in which a matrix effect of less than 15% was observed.
In the clinical validation, it appeared that the MFX concentration in DBS was significantly higher than in plasma. This can be explained by the unequal distribution of MFX between plasma and blood cells caused by a difference in binding capacity to plasma proteins and blood cells [24] . The slope of the regression lines of 1.49 (95% CI: 1.32-1.77) for finger blood/ plasma ratio and 1.59 (95% CI: 1.50-1.66) for venous blood/plasma ratio showed a higher concentrations in blood than in plasma. Despite these differences, excellent regression correlations were observed. The ratio can be used to translate the DBS concentration into a plasma concentration. Comparable MFX concentrations between DBS from finger prick and venous puncture were observed and thus suggested a similar MFX concentration between the venous and the finger capillary blood. This result also confirmed that the DBS sampling from the finger prick blood without a volumetric device was as reliable as using pipette.
Although the free drug concentration of MFX cannot be calculated based on a DBS result, it still enables the attending physician to make clinical decisions on dosing MFX in TB patients.
cONcLUsION
A rapid and fully validated LC-MS/MS method was developed for determining MFX in DBS.
V b is of minor influence compared to HT value on the analytical result. MFX concentrations obtained with DBS are significantly higher than the plasma concentrations because of the blood/plasma ratio but show a good correlation. As MFX is stable in DBS at room conditions for at least 4 weeks, the method can facilitate pharmacokinetic studies and TDM of this drug in remote rural areas.
